MINERALYS THERAPEUTICS INC
MLYSNASDAQπ #2180 by market capEarnings Mar 10 Β· PreUS Equity
$13.66βΌ $0.50 (β3.53%)
Market closed Β· at closeTrack MLYS
Get earnings, price moves & breaking news on Telegram
24hβΌ 3.5%
7dβΌ 10.9%
14dβΌ 11.0%
30dβΌ 33.5%
ytdβΌ 62.3%
1yβΌ 67.4%
π¦Market Cap
$1.21B
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $13.57 β $14.74
- 52-Week Range
- $13.57 β $45.00
- Volume (shares)
- 1,345,650
- Avg Volume (shares)
- β
- Shares Outstanding
- 88.4M
- Next Earnings
- 2027-03-10
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-4.36
- Dividend Yield
- β
- Dilution (1yr)
- +61.2%
MINERALYS THERAPEUTICS INC
MLYSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$171MβΌ β11.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$142MβΌ β14.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
80.5Mβ² +61.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$173Mβ² +$59M YoY
About MINERALYS THERAPEUTICS INC
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
17 analysts
Strong Buy5
Buy9
Hold3
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.